Your browser doesn't support javascript.
loading
The effects of golimumab on patient centric outcomes amongst rheumatoid arthritis patients in Greece. The GO-Q study.
Psaltis, Dimitrios; Settas, Loukas; Georgiadis, Athanasios; Koukli, Eftichia; Bounas, Andreas; Livieratos, Achilleas; Petrikkou, Evangelia; Kalogiannaki, Heleni; Repa, Argyro; Vassilopoulos, Dimitrios; Sidiropoulos, Prodromos.
Afiliación
  • Psaltis D; Private Practice, Serres, Greece.
  • Settas L; University of Thessaloniki, Thessaloniki, Greece.
  • Georgiadis A; Private Practice, Ioannina, Greece.
  • Koukli E; Private Practice, Athens, Greece.
  • Bounas A; OLYMPION"-General Clinic of Patra, Patras, Greece.
  • Livieratos A; MSD Pharmaceutical, Industrial and Commercial S.A., Medical Affairs, Athens, Greece.
  • Petrikkou E; MSD Pharmaceutical, Industrial and Commercial S.A., Medical Affairs, Athens, Greece.
  • Kalogiannaki H; Department of Rheumatology, Clinical Immunology and Allergy, University of Crete Medical School, Heraklion, Greece.
  • Repa A; Department of Rheumatology, Clinical Immunology and Allergy, University of Crete Medical School, Heraklion, Greece.
  • Vassilopoulos D; 2nd Department of Medicine and Laboratory Clinical Immunology-Rheumatology Unit, Hippokration General Hospital, National and Kapodistrian University of Athens School of Medicine, Athens, Greece.
  • Sidiropoulos P; Department of Rheumatology, Clinical Immunology and Allergy, University of Crete Medical School, Heraklion, Greece. sidiropp@uoc.gr.
Rheumatol Int ; 42(4): 639-650, 2022 Apr.
Article en En | MEDLINE | ID: mdl-35091757
This study aimed at assessing the impact of golimumab on health-related quality of life (HRQoL) and other patient-reported outcomes (PROs) in patients with rheumatoid arthritis (RA) in real-world settings. GO-Q was an observational, prospective, 12-month study, which recruited patients with moderate-to-severely active RA initiating golimumab treatment per label in rheumatology clinics and private practices. Primary endpoint was the change in PROs [EuroQol-5 Dimensions-3 Levels (EQ-5D-3L) questionnaire, Health Assessment Questionnaire Disease Index (HAQ-DI), and Work Productivity and Activity Index for RA (WPAI:RA)] after 12 months of treatment. Other endpoints included Disease Activity Score for 28 joints with erythrocyte sedimentation rate (DAS28-ESR), healthcare resource utilization, and golimumab adherence. Changes in continuous variables from baseline were evaluated with the paired t test. One hundred forty-five patients were recruited. The mean [standard deviation (SD)] EQ-5D-3L index increased significantly at 12 months versus baseline [from 0.427 (0.206) to 0.801 (0.229); p < 0.0001], with changes as early as 3 and 6 months (both p < 0.0001). Accordingly, there were statistically significant changes in all WPAI:RA domains from baseline to 3, 6, and 12 months (p < 0.0001). Patients' function improved gradually from the third month until the end of follow-up (p < 0.0001 for all time-points). Thirty (27.3%) and 60 (54.6%) patients achieved remission (DAS28-ESR < 2.6) and low disease activity (DAS28-ESR ≤ 3.2), respectively, at 12 months. Adherence rate to golimumab was high (mean [SD] 90.3% (7.5) at 12 months). In patients with moderate-to-severely active RA, golimumab significantly improved HRQoL, physical function, and work productivity and activity, with improvements in disease activity over 12 months in real-world settings.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Artritis Reumatoide / Antirreumáticos Tipo de estudio: Diagnostic_studies / Observational_studies Límite: Humans País/Región como asunto: Europa Idioma: En Revista: Rheumatol Int Año: 2022 Tipo del documento: Article País de afiliación: Grecia

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Artritis Reumatoide / Antirreumáticos Tipo de estudio: Diagnostic_studies / Observational_studies Límite: Humans País/Región como asunto: Europa Idioma: En Revista: Rheumatol Int Año: 2022 Tipo del documento: Article País de afiliación: Grecia